Furthering research on MAFLD: the APASL Metabolic fAtty lIver DiseasE coNsortium (MAIDEN)-Reference-Cited by-同舟云学术

Furthering research on MAFLD: the APASL Metabolic fAtty lIver DiseasE coNsortium (MAIDEN)

Published:2023-04-20 Issue:3 Volume:17 Page:546-549
ISSN:1936-0533
Container-title:Hepatology International
language:en
Short-container-title:Hepatol Int

Author:

George Jacob^ORCID,Lau George,Kawaguchi Takumi,Fan Jian-Gao,Ji-Dong Jia,Wang Fu-Sheng,Kumar Manoj,Sarin Shiv Kumar,Omata Masao,Wong Vincent Wai-Sun,Eslam Mohammed

Funder

National Health and Medical Research Council

University of Sydney

Publisher

Springer Science and Business Media LLC

Subject

Hepatology

Link

https://link.springer.com/content/pdf/10.1007/s12072-023-10530-z.pdf

Reference25 articles.

1. Mohammed Eslam M, Sarin SK, Wong VWS, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14(6):889–919

2. Eslam M, Sanyal AJ, George J. On behalf of an international consensus panel MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999–2014

3. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209

4. Liu J, Ayada I, Zhang X, et al. Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese a adults. Clin Gastroenterol Hepatol. 2022;20(3):573–582

5. Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:739–752

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Democratising the scientific method;Journal of Hepatology;2024-07

2. Serum PRO‐C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort;Liver International;2024-03

3. Serum PRO-C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease;2023-09-13